PARC builds on HBM4EU to harmonise human biomonitoring (HBM) across Europe, generating comparable data on exposure to phthalates and their alternatives in the general and occupational population. Biomarkers of these substances are analysed in human matrices (urine, blood, hair) from children, adolescents, and adults across Europe to capture aggregate exposure from all sources and pathways. It integrates bio-monitoring, analytical method development, and quality assurance to assess exposure levels and associated health effects.
Research focuses on aggregate exposure from multiple sources and pathways, evaluates temporal trends, identifies exposure determinants, and investigates expo-sure-effect relationships, including developmental outcomes such as neurodevelop-ment following prenatal exposure.
PARC further advances the derivation of HBM guidance values (HBM-GVs) and indoor air guideline values (IA-GVs), supports the development of new biomarkers (e.g. DnHexP secondary metabolites), and strengthens the integration of effect biomarkers and health outcomes into aligned studies.
Key Activities
- Harmonising HBM methods, QA/QC systems, and data handling for phthalates and alternatives
- Conducting EU-wide population and targeted occupational studies (e.g. waste and plastic recycling)
- Developing and validating analytical methods for phthalate metabolites and substitutes
- Investigating exposure pathways, determinants, and time trends
- Linking biomonitoring data with effect biomarkers and health outcomes
- Supporting regulatory use through guidance values and data platforms (EU HBM Dashboard)